Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
12:20pm, Monday, 25'th Apr 2022 Zacks Investment Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) first-quarter sales.
Is This Biotech Stock Worth the Trouble?
03:00pm, Saturday, 23'rd Apr 2022 The Motley Fool
The past year has been a bit stressful for this company and its shareholders.
Does Eli Lilly's Future Depend on its Alzheimer's Drug?
12:11pm, Saturday, 23'rd Apr 2022 The Motley Fool
Medicare's decision raises uncertainty about a key upcoming treatment.
Is This Biotech Stock Worth the Trouble?
11:00am, Saturday, 23'rd Apr 2022
The past year has been a bit stressful for this company and its shareholders.
Biogen Fails To Convince Benefits Of Alzheimer's Drug To European Regulator
12:33pm, Friday, 22'nd Apr 2022
Biogen Inc (NASDAQ: BIIB) has decided to withdraw the European marketing authorization application for its troubled Alzheimer's drug, aducanumab, after failing to convince the regulator of its bene
Biogen stock slides 2% after it withdraws authorization application with EU regulator
10:44am, Friday, 22'nd Apr 2022
Biogen Inc. shares BIIB, -2.71% fell 2% Friday, after the company said it has withdrawn the marketing authorization application for its controversial Alzheimer's treatment aducanumab with the European
Biogen Inc. (BIIB) Stock Moves -0.92%: What You Should Know
10:00pm, Thursday, 21'st Apr 2022 Zacks Investment Research
In the latest trading session, Biogen Inc. (BIIB) closed at $218.40, marking a -0.92% move from the previous day.
Analyst Ratings for Biogen
06:15pm, Thursday, 21'st Apr 2022 Benzinga
Over the past 3 months, 15 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company
Is Biogen Stock a Buy Now?
02:53pm, Thursday, 21'st Apr 2022 The Motley Fool
The stock has been surprisingly stable of late, which could be a promising sign.
Down 16% Since October, Could This Stock Make a Turnaround?
02:37pm, Thursday, 21'st Apr 2022 The Motley Fool
Biogen's recent collapse isn't the end of the road by a long shot.
Down 16% Since October, Could This Stock Make a Turnaround?
10:37am, Thursday, 21'st Apr 2022
Biogen's recent collapse isn't the end of the road by a long shot.
Why Biogen Inc. (BIIB) is Poised to Beat Earnings Estimates Again
04:10pm, Tuesday, 19'th Apr 2022 Zacks Investment Research
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Biogen Inc. (BIIB) is Poised to Beat Earnings Estimates Again
01:33pm, Tuesday, 19'th Apr 2022
Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biogen needs ‘this’ to unlock a 60% upside in its stock
07:51pm, Monday, 18'th Apr 2022 Invezz
Biogen Inc (NASDAQ: BIIB) stock could shoot up 60% if the biotech company reports positive results for its investigational Alzheimer’s drug Lecanemab in fall of 2022, says Mohit Bansal. Bansal’s b
Biogen needs ‘this' to unlock a 60% upside in its stock
03:51pm, Monday, 18'th Apr 2022
Biogen Inc (NASDAQ: BIIB) stock could shoot up 60% if the biotech company reports positive results for its investigational Alzheimer's drug Lecanemab in fall of 2022, says Mohit Bansal. Bansal's bull
